- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Brainsway Ltd(BWAY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BWAY
11/20/2026: BWAY (1-star) is currently NOT-A-BUY. Pass it for now.
Brainsway Ltd is a commercial-stage medical technology company specializing in non-invasive neurostimulation treatments for mental health disorders using its proprietary Deep TMS platform. The company's main strengths include its innovative H-coil technology and exclusive FDA clearance for treating obsessive-compulsive disorder, which support solid operating margins and a transition to profitability. Its primary growth story centers on expanding clinical indications and scaling recurring system leases across psychiatric practices. However, the company faces key risks from intensive market competition and third-party reimbursement dependencies. Brainsway suits growth-oriented investors willing to monitor execution milestones, clinic adoption rates, and reimbursement policy trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company delivers robust double-digit top-line growth and expands its addressable market through new clinical indications. |
| Momentum investor | Strong fit while signal remains positive | Positive earnings beats and rising system shipments can drive sharp upward momentum contingent on favorable technical breakouts. |
| Value investor | Mixed fit | While the company is profitable with a strong cash balance, its growth-adjusted valuation multiple requires careful entry evaluation. |
| Dividend investor | Weak fit | Brainsway does not pay dividends, retaining all earnings to fuel research and market expansion. |
| Low-risk investor | Weak fit | As a small-cap medical device stock, it experiences higher share price volatility and execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Small-cap medical technology equities frequently experience sharp swings based on quarterly execution and market sentiment. |
| Valuation risk | Medium | Priced for continued robust growth, any deceleration in system placement rates could compress valuation multiples. |
| Competition risk (alternative neuromodulation systems) | High | Intense competition from established device makers like Neuronetics challenges broader clinic acquisition rates. |
| Business quality | Medium / high | Proprietary H-coil technology and recurring lease models underpin a sound, defensible commercial framework. |
| Dividend income | Low / none | Income-focused investors receive no dividend yields since capital is reinvested into the business. |
| Execution risk | Medium | Sustaining profitability depends on successfully expanding clinical adoption and navigating regulatory approval pipelines. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 341.35M USD | Price to earnings Ratio 35.33 | 1Y Target Price 19.27 |
Price to earnings Ratio 35.33 | 1Y Target Price 19.27 | ||
Volume (30-day avg) 126.0K shares | Beta 0.13 | 52 Weeks Range 7.30 - 17.40 | Updated Date 11/21/2026 |
52 Weeks Range 7.30 - 17.40 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Devices
- BUY participation
- 33.3%
- Active BUY / eligible
- 2 / 6
- 30-Day BUY Count Change
- +2
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 60.94% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Deep TMS System Sales and Leases | Revenue generated from selling or leasing hardware units and proprietary H-coils to psychiatric clinics and hospitals. | Provides a predictable mix of upfront equipment sales and sticky, recurring lease revenues. |
| Services and Consumables | Ongoing maintenance contracts, technical support, clinical training, and pay-per-use session fees. | Creates high-margin recurring income streams once clinics integrate the platform into daily operations. |
| Geographic Exposure (North America & International) | Commercial operations anchored primarily in the United States alongside expanding international distributor networks. | Exposes the company heavily to U.S. insurance reimbursement trends and healthcare expenditure cycles. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-10 | When Before Market | Estimate 0.12 | Actual 0.1 |
Profitability
Profit Margin 15.56% | Operating Margin (TTM) 12.46% |
Management Effectiveness
Return on Assets (TTM) 4.05% | Return on Equity (TTM) 12.82% |
Valuation
Trailing PE 35.33 | Forward PE 11.56 | Enterprise Value 310.32M | Price to Sales(TTM) 5.62 |
Enterprise Value 310.32M | Price to Sales(TTM) 5.62 | ||
Enterprise Value to Revenue 4.75 | Enterprise Value to EBITDA 24.85 | Shares Outstanding 40.25M | Shares Floating 24.11M |
Shares Outstanding 40.25M | Shares Floating 24.11M | ||
Percent Insiders 6.12 | Percent Institutions 28.62 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

